DEADLINE NEXT WEEK: Berger Montague Advises AeroVironment, Inc. (NASDAQ: AVAV) Investors to Contact the Firm Before July 27, 2026

AeroVironment faces a class action lawsuit tied to the SCAR program after: a Jan. 20 stop-work order that drove shares down 15.77% (to $330.89), a March 2 SCAR reassessment that cut the stock another 17.42% (to $208.32), and a March 10 disclosure of a third-quarter 2026 operating loss of $179.0M including a $151.3M goodwill impairment. The company also said the Space Force terminated the SCAR contract and it must recompete, with the stock dropping 6.24% on March 11. Overall, the litigation follows a sequence of contract setbacks and significant impairment within the space division.

Analysis

The litigation itself is mostly a headline overhang; the economically relevant event is the market reassessing how much of AVAV’s valuation was implicitly tied to a space-related growth bridge that now looks uncertain. In defense, legal actions rarely move the base case unless they uncover revenue-recognition, disclosure-control, or governance issues; absent that, the larger near-term driver is whether management can replace or re-win the lost program without margin dilution.

Second-order effects likely favor competitors with cleaner government-program continuity. If the recompete drags, procurement dollars can migrate to better-capitalized primes or adjacent defense-tech names with lower single-program concentration, while AVAV may face a higher discount rate until visibility improves. That can also compress multiples across small-cap defense tech if investors start treating customer concentration and protest/termination risk as a broader underwriting issue.

The key catalyst window is 1-3 months: any disclosure on recompete timing, bridge work, or backlog replacement will matter more than the lawsuit cadence. Over 6-18 months, the real question is whether the space segment is structurally impaired enough to warrant a lower long-term EV/revenue multiple versus peers like KTOS, LHX, and NOC. This is a classic situation where the stock can stay weak even if the lawsuit is ultimately immaterial, because uncertainty around program reinstatement keeps estimate revisions negative.

Contrarian view: consensus may be overestimating the cash cost of the suit and underestimating the operational signal from the contract termination. If SCAR was a proof-point for AVAV’s space ambitions, the market may need to price a lower probability of cross-selling into adjacent programs. Conversely, if management quickly secures interim work or a faster recompete path, the litigation narrative should fade and the stock could retrace a chunk of the recent de-rating.

Key Decisions for Investors

• Use any AVAV relief rally over the next 1-2 weeks to establish a tactical short or buy put spreads; thesis is not the lawsuit, but the continued estimate and multiple compression from program uncertainty. Falsify on a clear replacement-contract disclosure or raised guidance tied to space backlog.
• Pair trade: short AVAV vs long KTOS or LHX for 1-3 months. The spread expresses confidence that cleaner program diversification and lower customer-concentration risk should command a premium while AVAV remains under a legal/contract cloud.
• If already long AVAV, trim exposure until management gives a specific recompete timeline and revenue bridge. The risk/reward is poor if the next catalyst is simply more legal filings without operational clarity.
• Watch for disclosure of reserve accruals, impairment follow-through, or any guidance cut in the next earnings cycle; that would be a better short trigger than the complaint itself. A stabilization in backlog and margins would invalidate the bearish thesis.
• For broader defense-tech exposure, prefer diversified primes over small-cap single-program names until the market re-prices customer concentration risk. XAR or a basket long of NOC/LHX over AVAV is the cleaner expression.